29 August 2018 - Our longstanding goal for medical care is to ensure that the right drug or device is delivered to the right patient at the right time. 

This vision is increasingly possible with the innovative products that are becoming available. Many of these opportunities are enabled by new technology platforms such as digital health, targeted medicines, and regenerative medicine, including cell and gene therapies. 

These new technologies offer transformative opportunities. But they also challenge the U.S. FDA to modernise its approach to evaluating new innovations. In many cases, we’ve had to refashion our regulatory approach to create more modern platforms that are better suited to the efficient evaluation of these advances.

Read FDA Blog